Lipella Pharmaceuticals Inc

NAS:LIPO (USA)   Ordinary Shares
$ 0.57 -0.074 (-11.49%) 11:08 PM EST
At Loss
P/B:
1.58
Volume:
39.43K
Avg Vol (2M):
22.07K
Trade In:
Volume:
39.43K
At Loss
Avg Vol (2M):
22.07K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for LIPO ( Lipella Pharmaceuticals Inc ) from 2022 to Jun 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Lipella Pharmaceuticals stock (LIPO) PE ratio as of Jun 22 2024 is 0. More Details

Lipella Pharmaceuticals Inc (LIPO) PE Ratio (TTM) Chart

To

Lipella Pharmaceuticals Inc (LIPO) PE Ratio (TTM) Historical Data

Total 377
  • 1
  • 2
  • 3
  • 4
  • 5
Lipella Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-22 At Loss 2024-04-17 At Loss
2024-06-20 At Loss 2024-04-16 At Loss
2024-06-18 At Loss 2024-04-15 At Loss
2024-06-17 At Loss 2024-04-12 At Loss
2024-06-14 At Loss 2024-04-11 At Loss
2024-06-13 At Loss 2024-04-10 At Loss
2024-06-12 At Loss 2024-04-09 At Loss
2024-06-11 At Loss 2024-04-08 At Loss
2024-06-10 At Loss 2024-04-05 At Loss
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-04-01 At Loss
2024-06-03 At Loss 2024-03-28 At Loss
2024-05-31 At Loss 2024-03-27 At Loss
2024-05-30 At Loss 2024-03-26 At Loss
2024-05-29 At Loss 2024-03-25 At Loss
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss

Lipella Pharmaceuticals Inc (LIPO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Lipella Pharmaceuticals Inc
NAICS : 541714 SIC : 2834
ISIN : US53630L1008

Share Class Description:

LIPO: Ordinary Shares
Description
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.